Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$653M |
| 2 |
Amazon
AMZN
|
+$602M |
| 3 |
ExxonMobil
XOM
|
+$473M |
| 4 |
Tesla
TSLA
|
+$437M |
| 5 |
Starbucks
SBUX
|
+$380M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$511M |
| 2 |
Netflix
NFLX
|
+$427M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$397M |
| 4 |
Nike
NKE
|
+$373M |
| 5 |
Microsoft
MSFT
|
+$365M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.68% |
| 2 | Healthcare | 17.69% |
| 3 | Consumer Discretionary | 13.09% |
| 4 | Industrials | 7.96% |
| 5 | Consumer Staples | 7.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3226
Lyell Immunopharma
LYEL
$337M
| $141K | ﹤0.01% |
+3,625
| New | +$131K |
|
3227
Gain Therapeutics
GANX
$92.1M
| $140K | ﹤0.01% |
42,800
-4,100
| -9% | -$11.4K |
|
3228
Drilling Tools International
DTI
$86.8M
| $139K | ﹤0.01% |
+43,300
| New | +$155K |
|
|
CMCT
3229
Creative Media & Community Trust
CMCT
$15M
| $137K | ﹤0.01% |
2
+1
| +100% | +$95.7K |
|
3230
Elicio Therapeutics
ELTX
$83M
| $137K | ﹤0.01% |
+16,466
| New | +$107K |
|
3231
Franklin Wireless
FKWL
$28.2M
| $137K | ﹤0.01% |
40,300
+17,700
| +78% | +$52.9K |
|
|
VBNK
3232
VersaBank
VBNK
$647M
| $137K | ﹤0.01% |
12,500
+600
| +5% | +$4.92K |
|
|
ZEPP
3233
Zepp Health
ZEPP
$78.6M
| $137K | ﹤0.01% |
24,125
-175
| -0.7% | -$879 |
|
3234
AmpliTech
AMPG
$152M
| $134K | ﹤0.01% |
71,085
-9,745
| -12% | -$17.2K |
|
3235
ASP Isotopes
ASPI
$539M
| $134K | ﹤0.01% |
74,768
-26,111
| -26% | -$38.1K |
|
|
DPU
3236
Top KingWin Ltd
DPU
$5.28M
| $133K | ﹤0.01% |
+121
| New | +$101K |
|
3237
Broadway Financial
BYFC
$110M
| $132K | ﹤0.01% |
19,495
-4,794
| -20% | -$32.6K |
|
|
CYAN
3238
DELISTED
Cyanotech Corp
CYAN
| $131K | ﹤0.01% |
147,409
-4,800
| -3% | -$3.84K |
|
3239
Gray Media Inc
GTN.A
| $130K | ﹤0.01% |
15,200
| – | – |
|
3240
MAIA Biotechnology
MAIA
$81.5M
| $130K | ﹤0.01% |
+111,200
| New | +$179K |
|
|
STRM
3241
DELISTED
Streamline Health Solutions
STRM
| $130K | ﹤0.01% |
20,380
-808
| -4% | -$5.15K |
|
3242
1-800-Flowers.com
FLWS
$261M
| $127K | ﹤0.01% |
11,800
-122,285
| -91% | -$1.05M |
|
3243
TScan Therapeutics
TCRX
$52.3M
| $127K | ﹤0.01% |
21,700
+4,000
| +23% | +$18.3K |
|
3244
Blue Ridge Bankshares
BRBS
$335M
| $126K | ﹤0.01% |
41,500
+25,300
| +156% | +$77.4K |
|
3245
Atomera
ATOM
$212M
| $125K | ﹤0.01% |
17,870
-4,530
| -20% | -$30.1K |
|
3246
Eledon Pharmaceuticals
ELDN
$286M
| $125K | ﹤0.01% |
69,173
+7,200
| +12% | +$10K |
|
3247
Finance of America Companies
FOA
$206M
| $125K | ﹤0.01% |
11,380
-1,330
| -10% | -$13.7K |
|
|
KORE
3248
DELISTED
KORE Group Holdings
KORE
| $125K | ﹤0.01% |
25,600
-7,659
| -23% | -$22K |
|
3249
Sagimet Biosciences
SGMT
$577M
| $125K | ﹤0.01% |
+23,000
| New | +$109K |
|
3250
Fathom Holdings
FTHM
$24.5M
| $124K | ﹤0.01% |
34,600
-100
| -0.3% | -$318 |
|
Similar funds
Jim Simons's Q4 2023 Portfolio in Review
As of Q4 2023, Jim Simons held 4,318 positions worth $64.6B, up 10% from $58.7B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons's Q4 2023 filing shows 702 new, 1,590 increased, 1,355 reduced and 633 closed positions. Its largest new stake was Amazon: 4,296,466 shares worth $653M. The largest sale was Berkshire Hathaway Class A, an estimated $511M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Jim Simons's largest Q4 2023 buy was Amazon: 4,296,466 shares worth $653M.
- Jim Simons added most to Meta Platforms (Facebook) in Q4 2023, an estimated $653M increase.
- Jim Simons's biggest Q4 2023 reduction was Berkshire Hathaway Class A, cutting an estimated $511M.
- Jim Simons fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $397M.
- Jim Simons's ten largest holdings make up 12% of its $64.6B portfolio in Q4 2023.
- Jim Simons opened 702 new positions and closed 633 in Q4 2023.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $64.6B.
Based on Renaissance Technologies's 13F filing for Q4 2023, filed 13 Feb 2024.